United States

Pharmazz

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Lyfaquin®, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India

Lead Product(s): Centhaquine

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).

Pharmazz

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Pharmazz Receives Marketing Authorization for Lyfaquin™ (centhaquine) from Indian Regulatory Agency

Lead Product(s): Centhaquine

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals Announces Proposed Public Offering

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Guggenheim Securities

Deal Size: $21.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 20, 2020

Details:

EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals and Vision Center Network Ink Agreement

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Vision Center Network of America

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 18, 2020

Details:

The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.